Shanghai Pioneer Holding (HKSE:01345) ROCE % : 16.98% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Shanghai Pioneer Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shanghai Pioneer Holding's annualized ROCE % for the quarter that ended in Dec. 2023 was 16.98%.

Shanghai Pioneer Holding ROCE % Historical Data

The historical data trend for Shanghai Pioneer Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Pioneer Holding ROCE % Chart

Shanghai Pioneer Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

13.36

9.53

21.37

27.25

16.55

Shanghai Pioneer Holding Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															21.68	29.45	26.79	16.80	16.98

Shanghai Pioneer Holding ROCE % Calculation

Shanghai Pioneer Holding's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	200.081	/	( ( (1755.104 - 528.034)	+	(1674.472 - 484.205) )	/ 2 )
	=	200.081	/	( (1227.07	+	1190.267)	/ 2 )
	=	200.081	/	1208.6685
	=	16.55 %

Shanghai Pioneer Holding's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	199.576	/	( ( (1568.128 - 407.785)	+	(1674.472 - 484.205) )	/ 2 )
	=	199.576	/	( ( 1160.343	+	1190.267 )	/ 2 )
	=	199.576	/	1175.305
	=	16.98 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Shanghai Pioneer Holding (HKSE:01345) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shanghai Pioneer Holding ROCE % Related Terms

Thank you for viewing the detailed overview of Shanghai Pioneer Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Pioneer Holding (HKSE:01345) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Shanghai Pioneer Holding Ltd (HKSE:01345) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.15, Lane 88 Wuwei Road, Putuo District, Shanghai, CHN, 200331

Website

http://www.pioneer-pharma.com

Shanghai Pioneer Holding Ltd is an investment holding company. It is engaged in the marketing, promotion, sales, and channel management service for pharmaceutical products and medical devices in China. The company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, gastroenterology, immunology, gynecology, and other therapeutic areas, and medical devices covering several medical specialties, including ophthalmology, orthopedics, odontology, and wound care. The majority of its revenue derives from the Sales of pharmaceutical products segment. The group operates mainly in PRC.

Shanghai Pioneer Holding (HKSE:01345) Headlines

No Headlines